Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.64Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -8.33%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in consumable revenue growth and strategic initiatives to reduce costs and enhance product offerings. However, challenges such as decreased instrument revenue, macroeconomic pressures, and adjustments in revenue guidance present notable concerns. The strategic pause in short-read sequencing development underscores the focus on long-read technology amidst a difficult funding environment.Company Guidance
During PacBio’s Q1 2025 earnings call, the company provided detailed guidance for the year, adjusting its revenue expectations to a range of $150 million to $170 million, down from the previous lower end due to newly implemented U.S.-China tariffs and potential NIH budget reductions. The call highlighted a 26% year-over-year growth in consumable revenue to $20.1 million, despite a 42% decline in instrument revenue to $11 million. The company shipped 12 Revio systems and 28 Vega systems, with a focus on expanding its clinical and hospital customer base. PacBio aims to achieve non-GAAP gross margins between 35% and 40% for 2025 and plans to lower annualized non-GAAP operating expenses by $45 million to $50 million by year-end through restructuring efforts. The company remains committed to turning cash flow positive by the end of 2027, driven by innovations in its long-read sequencing technology and strategic cost management.Record Consumable Revenue
Consumable revenue reached a record $20.1 million, reflecting 26% year-over-year growth and steady utilization across the growing base of Revio systems.
Strong Performance with Spark Chemistry
Customer uptake of Spark chemistry exceeded expectations with nearly 90% of Revio reagent kit shipments in the first quarter being Spark chemistry, leading to significant yield increases.
Expansion in Clinical and Translational Research
Growth among hospital and clinic customers, with notable placements in leading institutions like the Lurie Children's Hospital and Imagine Institute.
Restructuring Plan for Cost Reduction
Implemented a restructuring plan to reduce operating expenses, aiming for an annualized reduction of $45 million to $50 million by year-end.
New CFO Appointment
Jim Gibson, bringing over three decades of financial leadership experience, joins PacBio as the new CFO.
---
PACB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PACB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $1.20 | $1.12 | -6.67% |
Feb 13, 2025 | $1.48 | $1.85 | +25.00% |
Nov 07, 2024 | $2.45 | $2.30 | -6.12% |
Aug 07, 2024 | $1.53 | $1.67 | +9.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pacific Biosciences (PACB) report earnings?
Pacific Biosciences (PACB) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Pacific Biosciences (PACB) earnings time?
Pacific Biosciences (PACB) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PACB EPS forecast?
PACB EPS forecast for the fiscal quarter 2025 (Q2) is -0.18.
---